Arbutus Biopharma Corporation (ABUS)

$4.05

-0.1

(-2.41%)▲

Live

Performance

  • $3.98
    $4.15
    $4.05
    downward going graph

    1.73%

    Downside

    Day's Volatility :4.1%

    Upside

    2.41%

    downward going graph
  • $1.69
    $4.73
    $4.05
    downward going graph

    58.27%

    Downside

    52 Weeks Volatility :64.23%

    Upside

    14.29%

    downward going graph

Returns

PeriodArbutus Biopharma CorporationSector (Health Care)Index (Russel 2000)
3 Months
8.92%
3.6%
0.0%
6 Months
57.2%
10.2%
0.0%
1 Year
145.56%
19.6%
0.0%
3 Years
0.97%
16.8%
-23.0%

Highlights

Market Capitalization
777.8M
Book Value
$0.65
Earnings Per Share (EPS)
-0.45
PEG Ratio
0.0
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
-1238.24%
Return On Assets TTM
-30.59%
Return On Equity TTM
-59.96%
Revenue TTM
10.1M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-62.9%
Gross Profit TTM
-45.4M
EBITDA
-81.0M
Diluted Eps TTM
-0.45
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.38
EPS Estimate Next Year
-0.35
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Arbutus Biopharma Corporation(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 23.46%

Current $4.05
Target $5.00

Company Financials

FY18Y/Y Change
Revenue
5.9M
↓ 44.86%
Net Income
-57.1M
↓ 32.35%
Net Profit Margin
-967.8%
↓ 179.01%
FY19Y/Y Change
Revenue
6.0M
↑ 1.88%
Net Income
-153.7M
↑ 169.22%
Net Profit Margin
-2.6K%
↓ 1589.56%
FY20Y/Y Change
Revenue
6.9M
↑ 15.02%
Net Income
-65.2M
↓ 57.58%
Net Profit Margin
-943.17%
↑ 1614.19%
FY21Y/Y Change
Revenue
11.0M
↑ 58.92%
Net Income
-77.4M
↑ 18.62%
Net Profit Margin
-703.96%
↑ 239.21%
FY22Y/Y Change
Revenue
39.0M
↑ 255.11%
Net Income
-69.5M
↓ 10.21%
Net Profit Margin
-178.01%
↑ 525.95%
FY23Y/Y Change
Revenue
18.1M
↓ 53.51%
Net Income
-72.8M
↑ 4.89%
Net Profit Margin
-401.57%
↓ 223.56%
Q1 FY23Q/Q Change
Revenue
6.7M
↑ 7.08%
Net Income
-15.5M
↓ 32.51%
Net Profit Margin
-231.24%
↑ 135.63%
Q2 FY23Q/Q Change
Revenue
4.7M
↓ 30.45%
Net Income
-17.1M
↑ 10.55%
Net Profit Margin
-367.53%
↓ 136.29%
Q3 FY23Q/Q Change
Revenue
4.7M
↑ 0.15%
Net Income
-20.1M
↑ 17.61%
Net Profit Margin
-431.6%
↓ 64.07%
Q4 FY23Q/Q Change
Revenue
2.1M
↓ 53.95%
Net Income
-19.3M
↓ 3.94%
Net Profit Margin
-900.33%
↓ 468.73%
Q1 FY24Q/Q Change
Revenue
1.5M
↓ 28.58%
Net Income
-17.9M
↓ 7.44%
Net Profit Margin
-1.2K%
↓ 266.45%
Q2 FY24Q/Q Change
Revenue
1.7M
↑ 12.66%
Net Income
-19.8M
↑ 10.75%
Net Profit Margin
-1.1K%
↑ 19.85%
FY18Y/Y Change
Total Assets
227.9M
↓ 3.92%
Total Liabilities
27.7M
↓ 49.36%
FY19Y/Y Change
Total Assets
105.5M
↓ 53.69%
Total Liabilities
32.8M
↑ 18.38%
FY20Y/Y Change
Total Assets
137.1M
↑ 29.89%
Total Liabilities
35.1M
↑ 7.08%
FY21Y/Y Change
Total Assets
204.5M
↑ 49.17%
Total Liabilities
35.0M
↓ 0.19%
FY22Y/Y Change
Total Assets
195.4M
↓ 4.43%
Total Liabilities
58.6M
↑ 67.11%
FY23Y/Y Change
Total Assets
144.4M
↓ 26.11%
Total Liabilities
38.4M
↓ 34.46%
Q1 FY23Q/Q Change
Total Assets
191.2M
↓ 2.15%
Total Liabilities
47.3M
↓ 19.22%
Q2 FY23Q/Q Change
Total Assets
176.8M
↓ 7.53%
Total Liabilities
42.1M
↓ 10.95%
Q3 FY23Q/Q Change
Total Assets
158.6M
↓ 10.28%
Total Liabilities
39.3M
↓ 6.71%
Q4 FY23Q/Q Change
Total Assets
144.4M
↓ 8.98%
Total Liabilities
38.4M
↓ 2.34%
Q1 FY24Q/Q Change
Total Assets
150.3M
↑ 4.08%
Total Liabilities
35.7M
↓ 7.11%
Q2 FY24Q/Q Change
Total Assets
160.0M
↑ 6.49%
Total Liabilities
37.6M
↑ 5.43%
FY18Y/Y Change
Operating Cash Flow
-67.9M
↑ 39.71%
Investing Cash Flow
-4.1M
↓ 114.83%
Financing Cash Flow
55.6M
↑ 12.78%
FY19Y/Y Change
Operating Cash Flow
-71.0M
↑ 4.57%
Investing Cash Flow
28.3M
↓ 786.65%
Financing Cash Flow
37.5M
↓ 32.63%
FY20Y/Y Change
Operating Cash Flow
-51.4M
↓ 27.55%
Investing Cash Flow
-14.9M
↓ 152.61%
Financing Cash Flow
86.7M
↑ 131.59%
FY21Y/Y Change
Operating Cash Flow
-67.5M
↑ 31.28%
Investing Cash Flow
-12.7M
↓ 14.96%
Financing Cash Flow
137.2M
↑ 58.2%
FY22Y/Y Change
Operating Cash Flow
-35.4M
↓ 47.65%
Investing Cash Flow
-74.9M
↑ 491.12%
Financing Cash Flow
31.8M
↓ 76.82%
Q1 FY23Q/Q Change
Operating Cash Flow
-27.3M
↑ 60.69%
Investing Cash Flow
16.7M
↑ 31.51%
Financing Cash Flow
20.4M
↑ 84.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.6M
↓ 28.36%
Investing Cash Flow
1.4M
↓ 91.36%
Financing Cash Flow
4.7M
↓ 76.77%

Technicals Summary

Sell

Neutral

Buy

Arbutus Biopharma Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
2.72%
57.2%
145.56%
0.97%
370.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
NA
NA
0.0
-0.38
-0.6
-0.31
NA
0.65
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
Buy
$777.8M
370.84%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Arbutus Biopharma Corporation

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.53M → 1.72M (in $), with an average increase of 11.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -17.87M → -19.79M (in $), with an average decrease of 10.8% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 43.8%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    11.10%

  • Whitefort Capital Management, LP.

    6.82%

  • BlackRock Inc

    6.12%

  • Two Seas Capital LP

    4.54%

  • Vanguard Group Inc

    3.72%

  • Geode Capital Management, LLC

    1.76%

Company Information

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

Organization
Arbutus Biopharma Corporation
Employees
73
CEO
Mr. Michael J. McElhaugh
Industry
Health Technology

Discover More

FAQs